Drug intelligence / Profile preview

ABN201

Development stage: Preclinical
Lead developer: Abion
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

ABN201 is an antibody-cytokine fusion protein being developed by Abion for the treatment of solid tumors and other neoplastic conditions. The drug is designed to act as an interferon alpha/beta receptor (IFNAR) agonist by localizing interferon-beta (IFNβ) directly to the tumor microenvironment. This targeted delivery induces direct tumor cell death through interferon-receptor-induced, death receptor-mediated apoptosis and enhances the anti-tumor immune response by activating antigen-specific cytotoxic T-cells. ABN201 utilizes Abion's proprietary antibody-cytokine fusion platform and is intended for pan-carcinoma applications.

Targets

IFNAR (Immune system modulation via type I interferon receptor)MAGEA8 (Melanoma-associated antigen 8)

Beyond the preview

Go deeper on ABN201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABN201.

Explore the full profile